Vaccines (Jul 2020)

The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination

  • Nabila Seddiki,
  • Florence Picard,
  • Léa Dupaty,
  • Yves Lévy,
  • Véronique Godot

DOI
https://doi.org/10.3390/vaccines8030419
Journal volume & issue
Vol. 8, no. 3
p. 419

Abstract

Read online

We discuss here some of the key immunological elements that are at the crossroads and need to be combined to develop a potent therapeutic HIV-1 vaccine. Therapeutic vaccines have been commonly used to enhance and/or recall pre-existing HIV-1-specific cell-mediated immune responses aiming to suppress virus replication. The current success of immune checkpoint blockers in cancer therapy renders them very attractive to use in HIV-1 infected individuals with the objective to preserve the function of HIV-1-specific T cells from exhaustion and presumably target the persistent cellular reservoir. The major latest advances in our understanding of the mechanisms responsible for virus reactivation during therapy-suppressed individuals provide the scientific basis for future combinatorial therapeutic vaccine development.

Keywords